Transcarent and Accolade merger expected to be completed in second quarter of 2025

From GlobeNewswire: 2025-02-24 17:20:27

Transcarent and Accolade have announced the expiration of the waiting period for their merger under the HSR Antitrust Improvements Act of 1976. The transaction is expected to be completed in the second quarter of 2025 pending Accolade stockholder approval and other closing conditions. The merger aims to combine Transcarent’s AI-powered WayFinding solution with Accolade’s health advocacy and care services to improve healthcare navigation and delivery. Financial advisors involved in the merger include Evercore and Wilson Sonsini Goodrich & Rosati for Transcarent, and Morgan Stanley & Co LLC and Cooley LLP for Accolade.

Transcarent is known as the One Place for Health and Care, offering high-quality, affordable healthcare access through Care Experiences and WayFinding powered by generative AI. Accolade, a Personalized Healthcare company, provides virtual primary care, mental health services, expert medical opinions, and care navigation. The merger between Transcarent and Accolade aims to enhance consumer healthcare decision-making, providing tools and technology for better health outcomes. The companies have filed a definitive proxy statement regarding the merger with the SEC for stockholder approval.

Investors and security holders of Accolade are advised to carefully review the proxy statement and other related documents for details on the proposed merger with Transcarent. Forward-looking statements have been made regarding the benefits and timeline of the merger, with potential risks and uncertainties outlined. Additional information on factors affecting actual results is available in Accolade’s filings with the SEC. Media contacts for Transcarent and Accolade are provided for further inquiries.



Read more at GlobeNewswire: Transcarent and Accolade Announce Expiration of Hart-Scott